relax There is nothing new to get upset about. I have learned by watching the adoption of pca3, the amount of time and red tape hospitals must go through to get up and running a new test. My initial reaction after FDA approval is that we will see an instant revenue increase but what I did not understand is that just like with any new product/marker you have the early adoptors, those that were using the ASR and the ones that are the first to use novel techniques. What I did noy understand is it takes 6-8 months for interested hospitals to get up and running with new tests. Where I work, Urologists had to first show interest in the test, bring it up at a quarterly meeting and than present data on why the new test is worth while at the next meeting. Once the Urologists agreed on the test, they had to inform the lab that they were going to start with this marker, and beyond belief, it took 3 months for them to get ready. Everyone drags their feet, especially for investors. (I have seen this go on at three different hospitals)
Whats interesting is that these are centers ranked in the top 10 here in the U.S and several in the top 5 including the #1 center. One just started to offer the test in October and it should have been announced. What will happen now is that all the smaller hospitals will begin to offer the test because this is now the standard way the Top hospitals are handling prostate cancer. The smaller hospitals can either adopt the test or have their patients travel to get the test completed across town. This is when we will see a rapid adoption of the test.
I'm frustrated, just like all of us who have been with this company over the years. Pca3 will do very well and Hologic will stay quiet about their plans. Why should they say anything, when they know it will jump start this stock. We will see a move and an acquistion, but I have no idea at the price. I would guess $2.00. We are $30 million away from the jump to 16% and I would think Hologic knows that would trigger a spike up in price.